ICD-10-PCS 2027 procedure code
3E0230MIntroduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach
Short description: Introduce of Antneo, Moncln Ab, into Muscle, Perc Approach
Code last changed in FY2022 (effective October 1, 2021). Source: official FY2027 ICD-10-PCS release from CMS. Page updated September 29, 2026. About our data
About 3E0230M
3E0230M is the ICD-10-PCS code for a introduction procedure on the muscle using a percutaneous approach with antineoplastic (qualifier: monoclonal antibody). In ICD-10-PCS, introduction means putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
In plain terms, this corresponds to injection or infusion of biological response modifier [BRM] as an antineoplastic agent, the ICD-9-CM procedure title it maps to (99.28).
For a different body part, codes include 3E0130M (subcutaneous tissue), 3E0330M (peripheral vein), 3E0430M (central vein), 3E0530M (peripheral artery), 3E0630M (central artery), 3E0930M (nose) and 21 more.
It doesn't appear in the MS-DRG procedure index, so on its own it doesn't change the DRG assignment.
It has been valid since ICD-10-PCS took effect on October 1, 2015.
What each character means
- 1. Section
- 3Administration
- 2. Body System
- EPhysiological Systems and Anatomical Regions
- 3. Operation
- 0Introduction
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
- 4. Body System / Region
- 2Muscle
- 5. Approach
- 3Percutaneous
Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure
- 6. Substance
- 0Antineoplastic
Includes: Amivantamab Monoclonal Antibody; Lurbinectedin; RYBREVANT (tm) (Amivantamab Monoclonal Antibody); ZEPZELCA(tm) (Lurbinectedin)
- 7. Qualifier
- MMonoclonal Antibody
Other versions of this procedure
Different body system / region
Different qualifier
ICD-9-CM equivalent
Converter →- 99.28Injection or infusion of biological response modifier [BRM] as an antineoplastic agentapproximate
From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- FY2022 (effective 10/1/2021): Title revised — was “Introduction of Monoclonal Antibody into Muscle, Percutaneous Approach”
Common questions about 3E0230M
Is 3E0230M a valid ICD-10-PCS code for 2027?
- Yes. 3E0230M is valid for inpatient procedures from October 1, 2026 through September 30, 2027.
What is the ICD-9 procedure code for 3E0230M?
- The CMS GEMs map 3E0230M to ICD-9-CM 99.28 (Injection or infusion of biological response modifier [BRM] as an antineoplastic agent).